Brain activity predicts personalized antidepressant treatment

16-07-2015

 

 

Brain activity predicts personalized antidepressant treatment:

Implications for male-female differences

 


Nijmegen, July 17th, 2015 – Today results from the large multicenter randomized iSPOT-D study were published in Clinical Neurophysiology demonstrating that brain activity can assist in predicting antidepressant treatment outcome to commonly used antidepressant drugs. In addition, this study clearly demonstrated qualitative differences in brain activity between males and females with depression, with implications for predicting antidepressant treatment outcome. 

 

 

An international group of researchers including researchers from Research Institute Brainclinics and Utrecht University published results from the international multicenter iSPOT-D study (international Study to Predict Optimized Treatment in Depression). This study recruited 1008 patients with a depression who were randomized to three different commonly used antidepressants and 336 non-depressed individuals. The researchers measured brain electrical activity, also called EEG or QEEG. When looking at differences in brain activity between depressed patients and controls, only small differences were found, not suitable for diagnostic purposes. However, most analyses suggested qualitative differences in brain activation patterns for males and females with depression (see box on the right), where males with a depression had decreased ‘alpha’ brain activity on the back portion of the brain, and females had increased ‘alpha’ brain activity on the frontal part of the brain. 

 

 

Predicting personalized antidepressant treatment

The main aim of the study was to investigate if brain-based ‘biomarkers’, such as QEEG could predict treatment response. This study demonstrated that using a single biomarker – namely frontal alpha asymmetry – was able to predict treatment response and remission to escitalopram and sertraline (both belonging to the class of SSRI’s) for females only. This biomarker did not differ for the SNRI venlafaxine-XR nor for depressed males. A simulation demonstrated that when using this single biomarker to guide patients to an SSRI vs. an SNRI based on their individual brain activity, remission rates would have increased from 46% to 60% (an effective improvement in remission rate of 30%). “… the most surprising and promising aspect of this study is that the individual depressed patient can now be guided towards the most suitable treatment with a substantial improved chance for remission…’ said Martijn Arns, first author on the study. When replicated, this biomarker – possibly used in conjunction with other biomarkers identified in the iSPOT-D study – could help assist in the future of Personalized Medicine, where biomarkers are used to objectively guide patients to the right treatment.

 

Reference:

Arns, M., Bruder, G., Hegerl, U., Spooner, C., Palmer, D. M., Etkin, A., Fallahpour, K., Gatt, J.M., Hirshberg, L. & Gordon, E. (2015). EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study. Clinical Neurophysiology. doi:http://dx.doi.org/10.1016/j.clinph.2015.05.032

 

Note: This study was sponsored by Brainresource Ltd. But data-analysis and reporting were unconstrained. Also see: http://www.brainresource.com/personalized-medicine/biomarkers

  

Contact:

Research Institute Brainclinics: 
Dr. Martijn Arns
Bijleveldsingel 34
6524 AD Nijmegen, The Netherlands

Tel: +31 (0)6-48177919

URL: https://www.brainclinics.com 

Twitter: @Brainclinics